AI Summary
✦ ClarthaAlembic Pharmaceuticals is an integrated pharmaceutical company selling products in India and overseas. Its revenue spans branded therapies, generic formulations, and active pharmaceutical ingredients, with oncology, injectables, ophthalmology, and dermatology among key product areas. A 13% revenue beat and 12% quarterly profit increase indicate better-than-expected demand, supporting 10.3% annual revenue growth and 15.7% profit growth. Margins remain stable, but the reported debt-to-equity ratio of 25.22 implies material leverage, which can amplify returns while increasing financial risk. ROE is unavailable, limiting assessment of capital efficiency and earnings quality. At 23.5 times earnings, valuation appears fair rather than discounted, broadly consistent with its growth profile. The main open question is whether recent revenue outperformance can persist across international generics, specialty formulations, and API sales without margin pressure.
Valuation Metrics
Trading 5.7% below historical median. Valuation is declining — currently in the undervalued zone (z-score: -0.34). Confidence: 86%.
Live forward EPS implies next-12-month EPS of ₹48.02. Applying the stock's normalized valuation corridor produces a fair range of ₹1,046.36 to ₹1,303.26, with base value near ₹1,209.14 (+44.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹48.02
Forward P/E
17.5x
Base Fair Value
₹1,209.14
Fair Range
₹1,046.36 - ₹1,303.26
Upside To Base
+44.1%
Estimate Source
Live forward EPS
Growth Estimate
+12.1%
5Y Average
22.22
Current
23.74
Overvalued
27.14
Undervalued
21.79
5Y Average
14.49
Current
15.48
Overvalued
16.59
Undervalued
12.67
5Y Average
1.98
Current
2.12
Overvalued
2.28
Undervalued
1.69
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALKEM LABORATORIES LTD. ALKEMPharmaceuticals | +14.6% | 15.6% | 28.7x Undervalued | -74% vs avg | +8.7% |
GLAXOSMITHKLINE PHARMA LT GLAXOPharmaceuticals | +16.6% | 27.0% | 41.3x Undervalued | -63% vs avg | +0.5% |
BLISS GVS PHARMA LTD BLISSGVSPharmaceuticals | +29.8% | 13.9% | 41.2x Undervalued | -63% vs avg | +173.2% |
DABUR INDIA LTD DABURFMCG - Personal Products | +10.6% | 14.6% | 36.7x Undervalued | -67% vs avg | -17.6% |
AARTI INDUSTRIES LTD AARTIINDSpecialty Chemicals | +42.5% | 5.9% | 34.6x Undervalued | -69% vs avg | +35.0% |
COFORGE LIMITED COFORGEIT Services & Consulting | +49.9% | 9.6% | 36.4x Undervalued | -67% vs avg | +12.2% |
EXIDE INDUSTRIES LTD EXIDEINDBatteries | +17.7% | 4.9% | 44.5x Undervalued | -60% vs avg | +29.0% |
MAX FINANCIAL SERV LTD MFSLInsurance | -40.2% | 0.2% | 623.0x Premium | +462% vs avg | -5.7% |
ALEMBIC PHARMA LTD trades at a discount (23.7x vs peer avg 110.8x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALKEM LABORATORIES LTD., GLAXOSMITHKLINE PHARMA LT, BLISS GVS PHARMA LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.87K CrJun 2026Latest net profit
₹197 CrJun 2026Latest EPS
₹10.02Jun 2026Net margin
19.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,332 | 1,479 | 1,588 | 1,475 | 1,476 | 1,580 | 1,406 | 1,571 | 1,494 | 1,796 | 1,642 | 1,719 | 1,868 |
| Expenses + | 1,167 | 1,271 | 1,251 | 1,186 | 1,184 | 1,321 | 1,226 | 1,400 | 1,280 | 1,493 | 1,371 | 1,445 | 1,522 |
| Operating Profit | 166 | 207 | 337 | 288 | 291 | 259 | 180 | 171 | 214 | 303 | 272 | 274 | 346 |
| OPM % | 12% | 14% | 21% | 20% | 20% | 16% | 13% | 11% | 14% | 17% | 17% | 16% | 19% |
| Other Income + | 12 | 9 | 3 | 7 | 3 | 29 | 15 | 13 | 8 | 11 | -32 | 1 | 14 |
| Interest | 14 | 15 | 15 | 10 | 13 | 18 | 22 | 24 | 23 | 23 | 22 | 19 | 21 |
| Depreciation | 66 | 67 | 69 | 69 | 69 | 70 | 70 | 69 | 73 | 76 | 80 | 82 | 83 |
| Profit before tax | 98 | 134 | 257 | 216 | 213 | 200 | 104 | 92 | 126 | 216 | 139 | 173 | 256 |
| Tax % | 0% | 0% | 9% | 7% | 17% | 17% | 17% | 18% | 18% | 17% | 18% | -40% | 23% |
| Net Profit + | 98 | 134 | 233 | 202 | 176 | 166 | 86 | 75 | 104 | 179 | 114 | 243 | 197 |
| EPS in Rs | 4.96 | 6.81 | 11.87 | 10.27 | 8.96 | 8.43 | 4.37 | 3.83 | 5.27 | 9.12 | 5.82 | 12.37 | 10.02 |
| Raw PDF | |||||||||||||
| YOY Sales Growth % | 13.17% | 9.19% | 21.23% | 12.81% | 10.76% | 6.86% | -11.48% | 6.52% | 1.26% | 13.66% | 16.79% | 9.43% | 25.02% |
| Material Cost % | 31.30% | 31.75% | 31.01% | 28.57% | 26.34% | 29.87% | 26.91% | 35.00% | 27.93% | 32.51% | 30.73% | 29.96% | 29.71% |
| Employee Cost % | 24.58% | 22.07% | 20.59% | 24.07% | 24.16% | 23.26% | 26.26% | 23.77% | 26.53% | 22.72% | 24.44% | 23.68% | 22.29% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.87 | 0.00 | 0.00 | 0.00 | 0.00 | -42.23 | -24.76 | 0.00 |
| Other income normal | 11.84 | 8.95 | 3.30 | 7.22 | 3.15 | 16.06 | 15.46 | 13.21 | 7.79 | 11.49 | 10.73 | 25.88 | 14.04 |
| Exceptional items AT | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | -35 | -20 | 0 |
| Profit excl Excep | 98 | 134 | 233 | 202 | 176 | 155 | 86 | 75 | 104 | 179 | 149 | 263 | 197 |
| Profit for PE | 98 | 134 | 233 | 202 | 176 | 155 | 86 | 75 | 104 | 179 | 149 | 263 | 197 |
| Profit for EPS | 98 | 134 | 233 | 202 | 176 | 166 | 86 | 75 | 104 | 179 | 114 | 243 | 197 |
| YOY Profit Growth % | 297% | -9% | 96% | 55% | 81% | 16% | -63% | -63% | -41% | 16% | 74% | 249% | 90% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Announcement under Regulation 30 (LODR)-Earnings Call Transcript